Business Wire

Takeda Initiates Global Phase 3 Clinical Trial (TIDES) of Dengue Vaccine Candidate (TAK-003)

Del

Takeda Pharmaceutical Company Limited [TSE: 4502], (“Takeda”) today announced that it has vaccinated the first subject in the Tetravalent Immunization against Dengue Efficacy Study (TIDES), a Phase 3 double-blind, randomized and placebo-controlled trial of its live-attenuated tetravalent dengue vaccine candidate (TAK-003).

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160907006014/en/

TIDES will enroll approximately 20,000 healthy children between the ages of four and 16 years living in dengue-endemic countries in Latin America and Asia. The study will evaluate the efficacy of the vaccine candidate to protect subjects against symptomatic dengue fever caused by any of the four dengue virus serotypes, regardless of age and whether the individual has previously been exposed to the virus. The study will also evaluate vaccine safety and immunogenicity and will involve two doses of the vaccine candidate or placebo administered 90 days apart.1

According to the World Health Organization (WHO), dengue is the fastest spreading mosquito-borne viral disease.2 Forty percent of the world’s population lives under the threat of the dengue virus, which causes 390 million infections and more than 20,000 deaths each year around the world in people of all ages.3,4

“The initiation of Phase 3 trials for our dengue vaccine candidate is a critical milestone, bringing us closer to delivering a vaccine that can address important unmet needs in dengue prevention. This is a significant achievement for Takeda’s vaccine program and underscores our ongoing commitment to addressing critical global health threats,” said Rajeev Venkayya, MD, President of the Global Vaccine Business Unit at Takeda. “The progress of our dengue program, along with other recent achievements, such as Phase 2b field trial initiation for our norovirus vaccine candidate and our partnership with the Bill & Melinda Gates Foundation to develop a Sabin-strain inactivated poliovirus vaccine (sIPV), exemplify how we are researching, developing and providing vaccines to protect populations in need, wherever they may reside.”

While vector-control efforts are important, effective dengue disease prevention will also require vaccination. An ideal vaccine would have an acceptable safety profile and protect against all four types of the virus in both adults and children, whether or not they have been previously infected with dengue,” said Duane Gubler, Professor Emeritus and Founding Director, Signature Research Program in Emerging Infectious Disease, Duke-NUS Medical School.

TIDES will build on previous studies which have assessed the tolerability, safety and immunogenicity of the vaccine against all four dengue serotypes in multiple age groups to determine whether the vaccine helps prevent symptomatic dengue.5,6,7 In Phase 1 and Phase 2 studies, Takeda’s vaccine candidate induced neutralizing antibody responses against all four dengue virus serotypes across age groups and in both seropositive and seronegative individuals with no observed safety concerns.5,6,7 Interim results of one Phase 2 study (DEN-203) showed the vaccine to be generally safe and well tolerated.6 Results also showed that adults vaccinated with two doses had a sustained immune response against all four serotypes of the dengue virus, even after two years.6 Interim results of another Phase 2 study (DEN-204) showed an acceptable safety profile in endemic pediatric populations, as well as antibody responses against the four dengue serotypes in dengue seropositive and seronegative participants, with a sustained immune response through 180 days.7

About the Dengue Vaccine Candidate (TAK-003)

Takeda’s tetravalent dengue vaccine candidate (TAK-003) is based on a live-attenuated dengue serotype 2 virus (DENV-2), which provides the genetic ‘backbone’ for all four vaccine viruses.8 Takeda’s dengue vaccine is being developed to support the protection of populations and individuals at risk for dengue across geographies whether or not they have had previous exposure to dengue virus, including: children and adults, travelers and those living in endemic areas.

Phase 1 data has been published in the Journal of Infectious Diseases, Lancet Infectious Diseases, and Vaccine. Interim results of DEN-203, a Phase 2, placebo-controlled, multi-center, age-descending trial, were presented during the American Society of Tropical Medicine and Hygiene (ASTMH) meeting in October 2015.6 Interim results of DEN-204, a Phase 2, placebo-controlled, multi-center trial were presented during the 5th Annual Pan-American Dengue Research Network Meeting in May 2016.7

Takeda’s Commitment to Vaccines

Vaccines prevent more than two million deaths each year and have transformed global public health.9 For 70 years, Takeda has supplied vaccines to protect the health of people in Japan. Today, Takeda’s global vaccine business is applying innovation to tackle some of the world’s most challenging infectious diseases, such as dengue, norovirus and polio. Our team brings an outstanding track record and a wealth of knowledge in vaccine development, manufacturing and global access to advance a pipeline of vaccines to address some of the world’s most pressing public health needs.

About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited (TSE: 4502) is a global, R&D-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its research efforts on oncology, gastroenterology and central nervous system therapeutic areas. It also has specific development programs in specialty cardiovascular diseases as well as late-stage candidates for vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology and gastroenterology, as well as its presence in emerging markets, fuel the growth of Takeda. More than 30,000 Takeda employees are committed to improving quality of life for patients, working with our partners in health care in more than 70 countries. For more information, visit http://www.takeda.com/news.

1 Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children (TIDES) (2016). ClinicalTrials.gov. Accessed may 2016, from https://clinicaltrials.gov/ct2/show/NCT02747927?term=den-301&rank=1

2 World Health Organization (2015). Vector-borne diseases: Dengue. Accessed September 2016, from http://www.who.int/mediacentre/factsheets/fs387/en/index2.html

3 World Health Organization (2015). Dengue and severe dengue. Accessed May 2016, from http://www.who.int/mediacentre/factsheets/fs117/en/

4 Centers for Disease Control and Prevention (2015). Dengue homepage: Epidemiology. Accessed September 2016, from http://www.cdc.gov/dengue/epidemiology/

5 Osorio JE, Velez ID, Thomson C, et al. Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study. The Lancet Infectious diseases 2014;14(9):830-8.

6 Wallace, D. (2015). Persistence of neutralizing antibodies one year after two doses of a candidate recombinant tetravalent dengue vaccine in subjects aged from 1.5 to 45 years. Presented at 6th Annual Meeting, American Society of Tropical Medicine and Hygiene.

7 Saez-Llorens X., et al. (2016). Phase II, double-blind, controlled trial to assess the safety and immunogenicity of different schedules of Takeda’s Tetravalent Dengue Vaccine Candidate (TDV) in healthy subjects aged between 2 and <18 years and living in dengue endemic countries in Asia and Latin America. Presented at 5th Pan-American Dengue Research Network Meeting.

8 Huang, C. Y.-H., Osorio, J.E., et. al: Genetic and Phenotypic Characterization of Manufacturing Seeds for Tetravalent Dengue Vaccine (DENVax)

9 UNICEF Immunization Facts and Figures April 2013. Accessed September 2015, from http://www.unicef.org/immunization/files/UNICEF_Key_facts_and_figures_on_Immunization_April_2013(1).pdf

Contact information

For Takeda Pharmaceutical Company Limited
For media outside of Japan:
Elissa Johnsen
TEL: +1 224-554-3185
elissa.johnsen@takeda.com
or
For Japanese media:
Tsuyoshi Tada
TEL: +81-3-3278-2417
tsuyoshi.tada@takeda.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Changes in Executive Management at Sosei19.1.2018 01:54Pressemelding

Sosei Group Corporation (“Sosei” or the “Company”) (TOKYO: 4565), the world leader in GPCR medicine design and development, today announced that Dr. Fiona Marshall has resigned from her position as Executive Vice President and Chief Scientific Officer of Sosei to assume a senior role outside the Company. Dr. Marshall will leave Sosei at the end of February 2018. “As a co-founder of Heptares, I am very proud to have been associated with building a team of talented scientists over the past decade that has made many important breakthroughs in the field of GPCR stabilization and structure-based drug design, a unique technology that now underpins Sosei’s powerful drug discovery capability,” said Dr. Marshall. “With the team in excellent hands, I feel the time is right for me to move on to new challenges and I wish everyone at Sosei the best for what looks set to be an exciting future for the Company.” Peter Bains, Chief Executive Officer of Sosei, added: “Fiona has been a pivotal figure in

DXC Technology Named a 2018 Thomson Reuters Top 100 Global Technology Leader18.1.2018 23:12Pressemelding

DXC Technology (NYSE: DXC) has been recognized as a 2018 Top 100 Global Technology Leader by Thomson Reuters. The inaugural program identifies the tech industry’s most operationally sound and financially successful organizations. The Thomson Reuters Top 100 Global Tech Leaders study, the industry’s first holistic assessment of today’s leading tech companies, utilizes a 28-point data-driven algorithm to objectively identify organizations positioned to thrive in a complex and changing business environment. The patent pending methodology, developed by the Thomson Reuters Boston Innovation Lab, is based on eight principal pillars of performance: Financial Performance, Management and Investor Confidence, Risk and Resilience, Legal Compliance, Innovation, People and Social Responsibility, Environmental Impact, and Reputation. According to Thomson Reuters, these are the companies whose final scores across the pillars outshine over 5,000 other technology companies around the world. “DXC Techno

IFF Honors Dominique Ropion with Prestigious Master Perfumer Title18.1.2018 21:15Pressemelding

Regulatory News: This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180118006275/en/ Dominique Ropion (Photo: Business Wire) International Flavors & Fragrances Inc. (NYSE: IFF) (Euronext Paris: IFF), a leading innovator of sensory experiences that move the world, has named Dominique Ropion Master Perfumer. The Company’s designation recognizes perfumers who have demonstrated consistent and outstanding levels of creativity and craftsmanship in the art of perfumery, and exceptional leadership in and measurable impact on the industry. Mr. Ropion is the second perfumer at IFF recognized with the prestigious title, which was established in 2013. “At the heart of IFF are the people who consistently go above and beyond to passionately pursue their art and by doing so, revolutionize the industry,” said IFF Chairman & CEO Andreas Fibig. “In his 17 years with us, Dominique has consistently achieved this outstanding level of creativity and p

The Securities & Exchange Commission Announces Several Judgments And Injunctions Entered Against Defendants In The SEC v. Benger, et al. Litigation18.1.2018 19:21Pressemelding

The following statement is being issued by the Securities & Exchange Commission regarding Benger Fair Fund Class Action: Legal Notice BENGER FAIR FUND NOTICE The United States Securities and Exchange Commission authorized this Notice. This is not a solicitation from a lawyer. If you purchased or otherwise acquired China Voice Holding Corp., Biomoda, Inc., Pharma Holdings Inc., World Energy Solutions, Inc., Revolutions Medical Corp., Earthsearch Communications, Inc., and Essential Innovations Technology Corp. common shares from Defendants outside of the United States between March 1, 2007 and February 28, 2009, inclusive (the “Relevant Period”), you may be entitled to receive a monetary payment from the Benger Fair Fund (“Fair Fund”). Background In the action titled Securities and Exchange Commission v. Benger, et al. pending in the United States District Court for the Northern District of Illinois, Case No. 09-CV-676, several judgments and injunctions were entered against defendants Ha

Pharnext’s Pivotal Phase 3 Trial PLEO-CMT to Be Featured at the 22nd Edition of the Francophone Peripheral Nerve Society Conference18.1.2018 16:45Pressemelding

Regulatory News: Pharnext SA (Paris:ALPHA) (FR0011191287 - ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drugs based on the combination and repositioning of known drugs, today announced the Company will present an update from its ongoing pivotal Phase 3 clinical trial PLEO-CMT evaluating PXT3003 for the treatment of Charcot-Marie-Tooth type 1A disease (CMT1A), in an oral session during the 22nd edition of the Francophone Peripheral Nerve Society conference. The gathering will take place on January 26-27, 2018 in Paris (France). Details of the presentation are as follows: Date Time Session Friday January 26, 2018 From 3:03 to 3:15pm CET Selected Oral Communications Session Title: Status of the Pivotal Phase III Study (PLEO-CMT) Assessing the Efficacy and Safety of PXT3003 in the Treatment of Adult Patients with Charcot-Marie-Tooth type 1A Speaker : Prof. Shahram Attarian (Marseille) For more information about the event please visit : www.

ExaGrid Selected as Finalist for Storage Magazine’s 2017 “Product of the Year – Backup and DR Hardware” Award18.1.2018 16:45Pressemelding

ExaGrid®, a leading provider of hyper-converged secondary storage for backup, today announced that its EX Series of backup storage appliances with data deduplication has once again been selected as a finalist for TechTarget’s Storage magazine/SearchStorage.com 2017 “Product of the Year” award in the “Backup and DR Hardware” category. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180118006039/en/ These annual awards, now in their 16th year, showcase the year’s latest and greatest innovations in technology. “These premier awards are of particular import as the panel of judges are genuine experts in an increasingly complex segment of data center technology,” said Bill Andrews, CEO and President of ExaGrid. “To have been selected given their stringent criteria is an honour of which we’re quite proud.” Only ExaGrid uses a scale-out architecture with a unique loading zone, which addresses all of the scalability and performance cha

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom